– La Administración Nacional de Productos Médicos aprobó la comercialización de Stapokibart para el tratamiento de la dermatitis atópica de moderada a grave en adultos CHENGDU, China, 13 de septiembre de 2024 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) anunció hoy que la…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.